Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept (IMPACT)

Northwestern University

Status and phase: Completed; Phase 2

Conditions: Intracerebral Hemorrhage

Treatments: Drug: DDAVP injection (desmopressin acetate)

Study type: Interventional

Funder types: Other

Identifiers

NCT00961532

STU8168

Details and patient eligibility

About

The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.

Enrollment: 14 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Spontaneous intracerebral hemorrhage as documented by head CT scan
• Documented regular aspirin use or VerifyNow-ASA result of ≤ 550 aspirin reaction units (ARU), indicating anti-platelet medication

Exclusion criteria

• International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use
• History of von Willebrand disease
• Pregnancy
• Known hypersensitivity to DDAVP or desmopressin
• Active cardiovascular disease or unstable angina
• Hyponatremia or history of hyponatremia
• Current or historical deep venous thrombosis or pulmonary embolism

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

14 participants in 1 patient group

DDAVP

Experimental group

Description:

DDAVP 0.4 mcg/kg intravenously in 250 mL NS over 30 minutes

Treatment:

Drug: DDAVP injection (desmopressin acetate)